Urinary Excretion of 2/3-Monochloropropanediol (2/3-MCPD) and 2,3-Dihydroxypropylmercapturic Acid (DHPMA) after a Single High dose of Fatty Acid Esters of 2/3-MCPD and Glycidol: A Controlled Exposure Study in Humans

被引:18
作者
Abraham, Klaus [1 ]
Hielscher, Jan [1 ]
Kuhlmann, Jan [2 ]
Monien, Bernhard H. [1 ]
机构
[1] German Fed Inst Risk Assessment, Dept Food Safety, Max Dohrn Str 8-10, D-10589 Berlin, Germany
[2] SGS Germany GmbH, Weidenbaumsweg 137, D-21035 Hamburg, Germany
关键词
2/3-MCPD; biomarker of exposure; fatty acid esters; glycidol; urinary excretion;
D O I
10.1002/mnfr.202000735
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Scope 2- and 3-monochloropropanediol (2/3-MCPD) and glycidol are absorbed in the intestine after lipase-catalyzed hydrolysis of their fatty acid esters. Methods and results In an exposure study with 12 non-smoking participants, the complete urinary excretion of the metabolite 2,3-dihydroxypropylmercapturic acid (DHPMA) and of 2/3-MCPD is measured on four consecutive days before and after consumption of 50 g glycidyl ester-rich palm fat or 12 g 2/3-MCPD ester-rich hazelnut oil. After controlled exposure, urinary excretion rates of 2/3-MCPD per hour strongly increase, followed by a decrease with average half-lives of 5.8 h (2-MCPD) and 3.6 h (3-MCPD). After consumption of hazelnut oil, mean excretion rates are 14.3% (2-MCPD) and 3.7% (3-MCPD) of the study doses. The latter rate is significantly higher (4.6%) after consumption of palm fat, indicating partial conversion (about 5%) of glycidol to 3-MCPD under the acidic conditions in the stomach. The average daily "background" exposure is estimated to be 0.12 and 0.32 mu g per kg body weight (BW) for 2-MCPD and 3-MCPD, respectively. The relatively high and constant urinary excretion of DHPMA does not reflect the controlled exposure. Conclusion Urinary excretion of 2- and 3-MCPD is suitable as biomarker for the external exposure to the respective fatty acid esters.
引用
收藏
页数:10
相关论文
共 32 条
[1]   The hemoglobin adduct N-(2,3-dihydroxypropyl)-valine as biomarker of dietary exposure to glycidyl esters: a controlled exposure study in humans [J].
Abraham, Klaus ;
Hielscher, Jan ;
Kaufholz, Tobias ;
Mielke, Hans ;
Lampen, Alfonso ;
Monien, Bernhard .
ARCHIVES OF TOXICOLOGY, 2019, 93 (02) :331-340
[2]   Relative oral bioavailability of 3-MCPD from 3-MCPD fatty acid esters in rats [J].
Abraham, Klaus ;
Appel, Klaus E. ;
Berger-Preiss, Edith ;
Apel, Elisabeth ;
Gerling, Susanne ;
Mielke, Hans ;
Creutzenberg, Otto ;
Lampen, Alfonso .
ARCHIVES OF TOXICOLOGY, 2013, 87 (04) :649-659
[3]   Quantification of 3-MCPD and its mercapturic metabolite in human urine: validation of an LC-MS-MS method and its application in the general population [J].
Andreoli, Roberta ;
Cirlini, Martina ;
Mutti, Antonio .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2015, 407 (16) :4823-4827
[4]  
[Anonymous], 2000, IARC Monogr Eval Carcinog Risks Hum, V77, P469
[5]   Relative oral bioavailability of glycidol from glycidyl fatty acid esters in rats [J].
Appel, Klaus E. ;
Abraham, Klaus ;
Berger-Preiss, Edith ;
Hansen, Tanja ;
Apel, Elisabeth ;
Schuchardt, Sven ;
Vogt, Carla ;
Bakhiya, Nadiya ;
Creutzenberg, Otto ;
Lampen, Alfonso .
ARCHIVES OF TOXICOLOGY, 2013, 87 (09) :1649-1659
[6]   Toxicological assessment of 3-chloropropane-1,2-diol and glycidol fatty acid esters in food [J].
Bakhiya, Nadiya ;
Abraham, Klaus ;
Guertler, Rainer ;
Appel, Klaus Erich ;
Lampen, Alfonso .
MOLECULAR NUTRITION & FOOD RESEARCH, 2011, 55 (04) :509-521
[7]  
Barocelli E., 2011, EFSA SUPPORT PUBL, V8, P1, DOI [10.2903/sp.efsa.2011.EN-187, DOI 10.2903/SP.EFSA.2011.EN-187]
[8]  
BERGAU N, 2021, MOL NUTR FOOD RES
[9]   Carcinogenicity study of 3-monochloropropane-1,2-diol in Sprague-Dawley rats [J].
Cho, Wan-Seob ;
Han, Beorn Seok ;
Nam, Ki Taek ;
Park, Kidae ;
Choi, Mina ;
Kim, SeLlng Hee ;
Jeong, Jayoung ;
Jang, Dong Deuk .
FOOD AND CHEMICAL TOXICOLOGY, 2008, 46 (09) :3172-3177
[10]   Quantitative interpretation of human biomonitoring data [J].
Clewell, Harvey J. ;
Tan, Yu Mei ;
Campbell, Jerry L. ;
Andersen, Melvin E. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2008, 231 (01) :122-133